STERIS (NYSE:STE – Get Free Report) is scheduled to release its earnings data after the market closes on Tuesday, August 6th. Analysts expect STERIS to post earnings of $2.03 per share for the quarter. STERIS has set its FY 2025 guidance at 9.050-9.250 EPS and its FY25 guidance at $9.05 to $9.25 EPS.Parties that are interested in participating in the company’s conference call can do so using this link.
STERIS (NYSE:STE – Get Free Report) last posted its earnings results on Wednesday, May 8th. The medical equipment provider reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.41 by $0.17. The firm had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.41 billion. STERIS had a net margin of 6.95% and a return on equity of 13.73%. The company’s revenue was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.30 EPS. On average, analysts expect STERIS to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.
STERIS Trading Up 1.3 %
STE stock traded up $3.07 during midday trading on Tuesday, reaching $239.39. 70,099 shares of the company’s stock traded hands, compared to its average volume of 478,629. STERIS has a fifty-two week low of $195.47 and a fifty-two week high of $254.00. The business has a 50-day moving average price of $223.30 and a two-hundred day moving average price of $221.93. The company has a market capitalization of $23.66 billion, a P/E ratio of 62.45 and a beta of 0.83. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.08 and a quick ratio of 2.36.
STERIS Dividend Announcement
Analyst Upgrades and Downgrades
Several brokerages recently commented on STE. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a report on Friday, May 10th. StockNews.com upgraded shares of STERIS from a “hold” rating to a “buy” rating in a research note on Saturday, June 15th. JMP Securities reissued a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research report on Friday. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $225.00 target price (up from $220.00) on shares of STERIS in a research report on Friday, May 10th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $241.60.
Get Our Latest Stock Analysis on STE
Insider Transactions at STERIS
In other STERIS news, Director Jacqueline B. Kosecoff sold 4,584 shares of STERIS stock in a transaction on Monday, May 13th. The shares were sold at an average price of $231.53, for a total value of $1,061,333.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Cary L. Majors sold 2,024 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $232.13, for a total transaction of $469,831.12. Following the completion of the transaction, the senior vice president now owns 11,369 shares in the company, valued at approximately $2,639,085.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jacqueline B. Kosecoff sold 4,584 shares of the company’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $231.53, for a total value of $1,061,333.52. The disclosure for this sale can be found here. In the last quarter, insiders sold 7,762 shares of company stock worth $1,798,477. 1.14% of the stock is currently owned by corporate insiders.
About STERIS
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Featured Stories
- Five stocks we like better than STERIS
- Breakout Stocks: What They Are and How to Identify Them
- Aerospace Stock Fires Up a Solid EPS Beat and Raises Guidance
- 3 Small Caps With Big Return Potential
- Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
- Find and Profitably Trade Stocks at 52-Week Lows
- This Semiconductor Stock Is ON Track for a New High
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.